References
- US Food and Drug Administration. Center for Drug Evaluation and Research. NADAD 141-295 Palladia, toceranib phosphate tablets for dogs; 2009. Available from: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/860.
- London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009;15(11):3856–3865.
- Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503.
- Paech F, Bouitbir J, Krahenbuhl S. Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front Pharmacol. 2017;8:367.
- Walayat S, Shoaib H, Asghar M, et al. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systemic review. Ann Gastroenterol. 2021;34:235–240.
- Lee WM, Larson AM, Stravitz RT. AASLD position paper: the management of acute liver failure: update 2011. Hepatology; 2011. Available from: https://www.aasld.org/sites/default/files/201906/AcuteLiverFailureUpdate201journalformat1.pdf
- Yancey MF, Merritt DA, Lesman SP, et al. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. J Vet Pharmacol Ther. 2010;33(2):162–171.
- Yancey MF, Merritt DA, White JA, et al. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. J Vet Pharmacol Ther. 2010;33(2):154–161.